Prolactin increases the susceptibility of primary leukemia cells to NK and LAK effectors

Oberholtzer, Emanuela; Contarini, M.; Veglia, Fabrizio; Cossarizza, Andrea; Franceschi, Claudio; Geuna, Massimo; Provinciali, Mauro; Stefano, Giuseppina Di; Sissom, Janice F.; Brizzi, Maria Felice; Pegoraro, Luigi; Matera, Lina

doi:10.1016/s0960-5428(96)00019-8

Cited by 26 publications

(12 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was found that PRL improved cytotoxic function and proliferation of murine or human NK cells in vitro [26][27][28]. We have noted that PRL improves the differentiation of NK cells from human bone marrow CD34+ stem cells if cultured together with rhIL-15 (data not presented in this paper).…”

Section: Discussionmentioning

confidence: 68%

Recombinant Human Prolactin Improves Antitumor Effects of Murine Natural Killer Cells in vitro and in vivo

Sun

Wei

Zhang

et al. 2002

Neuroimmunomodulation

View full text Add to dashboard Cite

Objective: To verify the effect of prolactin on natural killer (NK) cells in vivo and its implications for NK cell immunotherapy. Methods: Recombinant human prolactin (rhPRL; 30 µg, i.p.) was administered to BALB/c mice and severe combined immunodeficiency (SCID) mice 1 day before harvesting splenocytes for ⁵¹Cr release assay to examine the effects of rhPRL on NK cells of normal mice. rhPRL (10 µg, i.p., every other day for a total of 5 injections) was administered to BALB/c mice after syngeneic bone marrow transplantation (SBMT) to determine its effects on NK cell reconstitution. CT26 tumor cells were injected into BALB/c mice intravenously on day 0, and interleukin (IL)-15-cocultured activated syngeneic NK cells (IL-15-NK) from SCID mice were intravenously injected into tumor-bearing BALB/c mice on day 1. The improvement of antimetastasis effects and survival of tumor-bearing mice by rhPRL were checked. Results: BALB/c and SCID mice receiving one rhPRL injection exhibited a significant increase in cellular cytotoxicity against YAC-1 target tumor cells; the specific lysis was enhanced from 12.5 to 17.3% in BALB/c mice and from 27.8 to 51.2% in SCID mice. BALB/c mice continuously receiving rhPRL injections exhibited significant increases in NK cell (DX5-positive) contents and cellularity in both the bone marrow and spleen in the SBMT model. The bone marrow NK cell contents were improved from 1.53 to 3.13% after rhPRL injection. NK cells from SCID mice were then cultured with recombinant human IL-15 (rhIL-15; 6,000 IU/ml), rhPRL (10 ng/ml) or rhIL-15 plus rhPRL for 25 days. The cytotoxicity and cellularity were enhanced by rhPRL when tested on day 10, when comparing the rhIL-15 plus rhPRL group with the rhIL-15 group or rhPRL group, respectively. In the adoptive cellular immunotherapy study, the IL-15-NK plus IL-15 plus rhPRL group showed significantly lower numbers of lung metastases and longer survival than the IL-15-NK plus IL-15 group; the mean survival interval was prolonged from 31.5 to 53.7 days. Conclusion: These results indicate that rhPRL is possibly an important regulator of NK cells and a potential biologic product for immunotherapy.

show abstract

Section: Discussionmentioning

confidence: 68%

Recombinant Human Prolactin Improves Antitumor Effects of Murine Natural Killer Cells in vitro and in vivo

Sun

Wei

Zhang

et al. 2002

Neuroimmunomodulation

View full text Add to dashboard Cite

show abstract

“…Administration of PRL is also associated with increased graft rejection (418, 481) and an increase in T cell engraftment (419). In natural killer cells, PRL has been reported to increase DNA synthesis (464) and augment cytotoxic effects (463), as well as increasing susceptibility of primary leukemic cells (462).…”

Section: F Immunoregulation and Protectionmentioning

confidence: 99%

Prolactin (PRL) and Its Receptor: Actions, Signal Transduction Pathways and Phenotypes Observed in PRL Receptor Knockout Mice

1998

View full text Add to dashboard Cite

“…As both cell division and transcription of the erythropoietin-R gene are triggered by PRL in these cells, the presence of a long form (able to transduce signals) is postulated [46 and L.M., unpublished results]. Receptors for PRL were detected by the same antibody on primary AML blasts of the M4 type, and stimulation by either hPRL or recombinant hPRL increased both the DNA synthetic activity and the susceptibility of these cells to lymphokine-activated killer (LAK) activity [47]. Attempts to confirm these data with the promyelocytic HL60 cell line were unsuccessful (L.M., unpublished results).…”

Section: Prl-rmentioning

confidence: 99%

A role for growth hormone and prolactin in leukaemia and lymphoma?

Hooghe

Merchav

Gaïdano³

et al. 1998

CMLS, Cell. Mol. Life Sci.

Self Cite

View full text Add to dashboard Cite

Growth hormone (GH) and prolactin (PRL) quality as lymphohaemopoietic growth and differentiation factors, and so does insulin-like growth factor (IGF)-I, which mediates many of GH activities. Although there is only limited evidence that endocrine, paracrine or autocrine GH or PRL play a role in human leukaemia and lymphoma, the expression of these factors or their receptors may have diagnostic or therapeutic implications. Indeed, the participation of GH, PRL or IGF-I in the development or progression of certain haematological malignancies or to the antitumour immune response has been documented. Examples discussed in this review include a rat lymphoma in which the PRL receptor acts as an oncogene; the rat Nb2 lymphoma, which is dependent on PRL for growth; and experiments showing that PRL stimulates natural killer cell activity and the development of lymphokine-activated killer cells.

show abstract

Prolactin increases the susceptibility of primary leukemia cells to NK and LAK effectors

Cited by 26 publications

References 44 publications

Recombinant Human Prolactin Improves Antitumor Effects of Murine Natural Killer Cells in vitro and in vivo

Recombinant Human Prolactin Improves Antitumor Effects of Murine Natural Killer Cells in vitro and in vivo

Prolactin (PRL) and Its Receptor: Actions, Signal Transduction Pathways and Phenotypes Observed in PRL Receptor Knockout Mice

A role for growth hormone and prolactin in leukaemia and lymphoma?

Contact Info

Product

Resources

About